Bio-Thera Solutions’ BAT2206 Biosimilar of Stelara Gains FDA Approval
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) announced that it has received Biologic License Application (BLA)...
Hainan Introduces New Pricing Rules for Digital Therapeutics Effective June 1
The Hainan provincial healthcare security administration and health commission bureaus jointly issued the “Notice on...
Kanghong Pharma Wins NMPA Approval for KH617 in Glioblastoma Trial
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that it has received clinical...
Shandong Kanghua Biotechnology Announces IPO Plans on Beijing Stock Exchange
China-based Shandong Kanghua Biotechnology Co., Ltd., a developer of in vitro diagnostic (IVD) reagents, has...
Salubris Pharma Inks Licensing Deal for Gowell’s GW906 in Greater China
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced a licensing agreement with compatriot firm...
Walvax Biotechnology Secures Exclusive Rights to Notitia’s Gut Microbiota Therapy
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) announced an exclusive sublicense agreement with US-based Notitia...
Guangdong Zhongsheng Wins Peking University People’s Hospital Nod for RAY1225 Phase III Trials
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from...
Jemincare’s Irinotecan Liposome Injection Gains NMPA Approval for Pancreatic Cancer
China-based Jiangxi Jemincare Group announced that it has received marketing approval from the National Medical...
Novo Nordisk’s Wegovy Demonstrates Early Cardioprotective Effects in SELECT Trial
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced groundbreaking secondary analysis results from...
GSK’s Blenrep Recommended for EU Approval in Multiple Myeloma
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that its Blenrep (belantamab mafodotin) has been...
Dizal Pharma Presents DZD8586 and DZD6008 Results at ASCO 2025
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical results for its investigational...
Abbisko Therapeutics’ FGFR4 Inhibitor Irpagratinib Granted Breakthrough Therapy Designation for HCC
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that it has received Breakthrough Therapy...
Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline
China-based Elpiscience Biopharmaceuticals, Inc. has filed for an initial public offering (IPO) with the Hong...
Medilink Therapeutics Collaborates with Wuhan Union Hospital on Clinical Trials
Suzhou-based Medilink Therapeutics announced a clinical study collaboration agreement with Union Hospital, Tongji Medical College,...
Duality Biologics Receives FDA IND Approval for EGFR/HER3 ADC AVZO-1418
Duality Biologics (HKG: 9606), a developer of antibody conjugate drugs (ADCs) operating in the United...
Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received approval from...
Bayer’s Eylea 8 mg Close to EU Approval for Longer Treatment Intervals
German pharmaceutical giant Bayer (ETR: BAYN) announced that the European Medicines Agency’s (EMA) Committee for...
Sichuan Kelun-Biotech Finalizes Licensing Deal for TSLP Monoclonal Antibody
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received the upfront...
Roche’s Itovebi Recommended for EU Approval in PIK3CA-Mutated Breast Cancer
Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that its Itovebi (inavolisib) has been...
Jenscare Announces Positive 30-Day Results for LuX-Valve Plus in TRINITY Study
Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...